Spero Therapeutics
SPRO
60 hedge funds and large institutions have $93.2M invested in Spero Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 7 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
0.19% more ownership
Funds ownership: 56.54% → 56.73% (+0.19%)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
2% less funds holding
Funds holding: 61 → 60 (-1)
10% less capital invested
Capital invested by funds: $104M → $93.2M (-$10.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$5.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 3 |
BlackRock
New York
|
+$1.11M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$705K |
| 5 |
AG
Artal Group
Luxembourg
|
+$670K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.49M |
| 2 |
O
OrbiMed
New York
|
-$1.27M |
| 3 |
AIC
AWM Investment Company
New York
|
-$691K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$566K |
| 5 |
JP Morgan Chase
New York
|
-$486K |
SPRO Hedge Fund Activity: Q1 2020 in Review
60 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2020, worth a combined $93.2M — down 10% from $104M a quarter earlier.
Fund positioning in SPRO was balanced in Q1 2020: 7 funds opened new positions, 7 closed out, 31 added to existing stakes and 15 trimmed.
The largest buyer was Aquilo Capital Management, adding an estimated $5.85M. The largest seller was BVF Inc, cutting an estimated $2.49M.
- 60 institutional investors held Spero Therapeutics (SPRO) as of Q1 2020, down from 61 in Q4 2019.
- Funds reported $93.2M of Spero Therapeutics stock for Q1 2020, down 10% quarter-over-quarter.
- 7 funds opened new Spero Therapeutics positions in Q1 2020 and 7 closed out, a net change of 0 holders.
- The largest Spero Therapeutics buyer in Q1 2020 was Aquilo Capital Management, an estimated $5.85M added.
- The largest Spero Therapeutics seller in Q1 2020 was BVF Inc, an estimated $2.49M sold.
Based on aggregated 13F filings for Q1 2020.